Next Phase Newsletter

The firm is a philanthropic venture firm established by the a family trust in 2009 to accelerate the development of promising technologies for the diagnosis and treatment of cardiovascular and neurovascular disease through targeted investments. The firm makes 4-5 investments each year of approximately $1 million into privately-held companies worldwide at both the seed and early venture stages. The firm operates under an evergreen structure and has made 47 investments to date. 

While the firm is focused on cardiovascular, neurovascular and metabolic diseases (e.g., diabetes, dyslipidemia and obesity), the firm invests across all technology sectors including biotech, medtech, diagnostics, and regenerative medicine. Broadview looks to invest in companies where its investment will help move the company to a value inflection point necessary for the next and larger financing round. 

The firm invests in technologies that have the potential for a clear impact on patient therapy and/or standard of care, an adequate level of IP protection, well-defined use of proceeds with quantifiable and achievable milestones, and a clear understanding of the next round of fundraising needs including size and likely sources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The company is a publicly traded company focused on oncology therapeutics. The firm is seeking therapeutic opportunities in the oncology space. The firm is looking to partner and collaborate as well as in-license, but is primarily seeking partnerships. The firm seeks assets that have at the very least cellular proof of concept, but prefers companies to have some animal data or are approaching pre-IND studies. The firm is also willing to partner with unique and differentiated drug discovery platform companies. The firm will partner globally, but primarily partners with US and Europe-based companies. 

The firm is interested only in oncology and immuno-oncology assets in high unmet tumor indications including RCC and HCC. For modality, the firm is interested only in small molecule and biologics. The firm is willing to consider therapeutics targeting both solid and liquid tumors. The firm will also partner with drug discovery companies, such as those using AI-based technologies to identify new therapeutic biology, as well as platform companies. 

The firm will only partner with companies that have a strong IP position and a clear differentiating discovery and development strategy. The firm looks for startups with unique “First-in-Class” therapeutics and platforms. 

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a private investment firm with offices in the USA. The firm is actively investing in early-stage life science companies, primarily from Series A to beyond. Typical investment size ranges between $5-20M USD, and the firm works together with its network of other active investment firms and family offices to form investment syndicates. The firm is focused on companies based in USA and Canada, but is open to evaluating highly promising companies beyond North America. 

The firm invests in therapeutics and devices, and digital health to a much lesser extent. The firm will not consider wearables. With regards to therapeutics, the firm is most interested in clinical stage companies (pre-clinical will most likely be considered too early stage) in the anti-infective space. The firm does look at other modalities and indications given that they are fairly advanced clinical assets. In terms of medical devices, the firm will consider those that are very close to, or already gained FDA approval. The firm is agnostic in terms of subsectors and indications, but is most interested in technologies that address a large market and can be applied in a wide scale. The firm has reviewed technologies in ophthalmology, cardiovascular, and pulmonary indications with positive interest. 

The firm has no specific company or management team requirements, though strong intellectual property is considered a huge plus. The firm generally acts as a co-investor, but also engages fellow investors in their network to syndicate investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture capital firm was founded in 2012 and is based in San Diego, CA. The firm invests in a wide range of data-driven products that integrate AI, machine learning, and IoT. The firm is backed by a management team with a long, successful track record of building tech companies. The firm invests in the company’s early stages with an initial check size of $250 K with follow-on investments as the company matures, with equity and convertible loan as the preferred capital structures. The firm focuses on US-based companies, but may consider international companies with strongly innovative products that they can bring to the US market.

The firm will look at a range of verticals in the life sciences sector as long as there is a strong data-driven component in the company’s product. Sectors of interest include healthcare IT/digital health. The firm will not consider therapeutics or medical devices unless there is a heavy data component. The firm’s previous investments include an AI-driven image analysis platform for cancer detection, a computational DNA analysis platform for personalized cancer treatments, and a DNA amplification technology based on electric field-induced pH changes. The firm has their own AI Lab of top data scientists, so the company does not have to have the AI experts as long as they have the data, know how to get the data, and what information would be valuable to retrieve via machine learning applications.

The firm will work with companies backed by founders with deep domain expertise. The firm prefers deploying the venture studio model to help co-found companies, deploy their AI Lab experts, and will always take a board seat in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture caputal firm was founded in 1996 and has offices in Palo Alto, CA, Shanghai, Beijing, Hongkong, Taipei. The firm is currently making investments in early-stage healthcare companies from one of its funds. The firm invests exclusively in the healthcare sector; the firm invests primarily in the USA and Greater China but will also invest in other regions such as Europe and ASEAN countries. Within China, the firm makes growth investments in companies but also find some companies with interesting and innovative product in recent years there; in the USA and other regions, the firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. The firm makes investments of typically $5-20 million. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, gene therapy, cell therapy, are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. Healthcare AI is an area we are interested and exploring. For devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, the firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture arm of the world’s leading provider of products and services for people with chronic kidney failure is headquartered in Germany. The firm has offices in USA, Germany, and Israel, and is actively seeking early-stage investment opportunities that align with Fresenius’ core businesses. Typical size of investment is around $5M, and the firm focuses on Series A to B rounds. The firm is open to global opportunities.

The firm is interested in products and technologies across therapeutics, medical devices, diagnostics, and digital health that target the following therapeutic sectors: chronic kidney disease and dialysis, intensive care medicine, cardiovascular diseases, autoimmune diseases, diabetes, and other kidney-related diseases. In terms of medical devices, the firm is open to 510k and PMA regulatory pathways.

The firm is open to working with all types of management teams. The firm can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.